GPCR · Structure Therapeutics Inc.

$49.12 -1.68 (-3.31%) At close · Jul 24

Market Cap

$10.47B

213.22M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Raymond Stevens	CEO	$672,094	—	$2,387,996	$4,846,926	$508,871	$14,000	$8,429,887
Jun Yoon	CFO	$530,530	—	$1,193,998	$2,423,463	$309,075	$10,529	$4,467,595
Blai Coll	Chief Medical Officer	$492,813	—	$820,866	$1,666,117	$253,151	$14,000	$3,246,947
Xichen Lin	Chief Scientific Officer	$505,313	—	$567,150	$1,151,143	$257,103	—	$2,480,709
Yingli Ma	CTO	$429,768	—	$447,734	$908,788	$212,592	—	$1,998,882

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Raymond Stevens	CEO	$634,246	—	$1,582,514	$3,173,843	$334,447	$13,800	$5,738,850
Xichen Lin	Chief Scientific Officer	$476,542	—	$1,007,057	$2,019,700	$185,799	$1,668	$3,690,766
Blai Coll	Chief Medical Officer	$449,138	—	$1,296,452	$1,504,500	$187,150	$13,800	$3,451,040
Jun Yoon	CFO	$482,300	—	$698,761	$1,401,433	$217,068	$13,800	$2,813,362

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Raymond Stevens	CEO	$595,852	—	—	$6,500,534	$281,325	$13,200	$7,390,911
Jun Yoon	CFO	$441,262	—	—	$3,047,125	$173,183	$13,200	$3,674,770
Mark Bach	Head of Clinical Development and Medical Affairs	$485,812	—	—	—	$173,045	$13,200	$672,057

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Raymond Stevens	CEO	$487,333	—	—	—	$247,500	$12,500	$747,333
Mark Bach	Head of Clinical Development and Medical Affairs	$466,375	—	—	—	$149,499	$12,500	$628,374

Key facts CIK 1888886 CUSIP 86366E106 13F (30d) 20 filings 20 filers Visit website Investor relations